Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 VBI VaccinesCollegium PharmaceuticalOdonate TherapeuticsADVANZ PHARMAAmphastar Pharmaceuticals
SymbolNASDAQ:VBIVNASDAQ:COLLNASDAQ:ODTOTCMKTS:CXRXFNASDAQ:AMPH
Price Information
Current Price$2.95$23.60$3.55$16.84$17.62
52 Week RangeBuyHoldHoldN/AHold
MarketRank™
Overall Score1.51.41.80.51.5
Analysis Score3.61.13.00.02.1
Community Score3.22.52.12.32.6
Dividend Score0.00.00.00.00.0
Ownership Score0.80.02.50.00.8
Earnings & Valuation Score0.03.11.30.01.9
Analyst Ratings
Consensus RecommendationBuyHoldHoldN/AHold
Consensus Price Target$7.00$25.00$19.33N/A$21.67
% Upside from Price Target137.29% upside5.93% upside444.60% upsideN/A22.97% upside
Trade Information
Market Cap$713.75 million$818.85 million$128.17 million$823.92 million$837.44 million
Beta2.141.270.66N/A0.87
Average Volume6,455,847543,6333,622,04514,896194,287
Sales & Book Value
Annual Revenue$2.22 million$296.70 millionN/A$508.32 million$322.36 million
Price / Sales337.532.80N/A1.622.61
CashflowN/AN/AN/AN/A$0.72 per share
Price / CashN/AN/AN/AN/A24.42
Book Value$0.50 per share$2.61 per share$5.06 per share$0.31 per share$9.11 per share
Price / Book5.909.04N/A54.341.93
Profitability
Net Income$-54,810,000.00$-22,720,000.00$-111,820,000.00$-196,020,000.00$48.94 million
EPS($0.46)($0.68)($4.05)N/A$0.36
Trailing P/E RatioN/A48.16N/AN/A125.86
Forward P/E RatioN/A14.30N/A15.87
P/E GrowthN/A0.73N/AN/AN/A
Net Margins-2,837.73%5.71%N/A-19.88%1.97%
Return on Equity (ROE)-36.69%12.64%-85.75%N/A5.50%
Return on Assets (ROA)-28.29%3.15%-71.45%-3.08%4.04%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.10%1.27%N/AN/A0.07%
Current Ratio9.06%1.08%6.68%1.75%2.86%
Quick Ratio8.95%1.01%6.68%1.24%1.73%
Ownership Information
Institutional Ownership Percentage52.13%N/A96.00%N/A55.08%
Insider Ownership Percentage10.50%8.08%48.90%N/A29.80%
Miscellaneous
Employees1272341344291,980
Shares Outstanding254.01 million35.20 million38.60 million48.91 million47.69 million
Next Earnings Date5/5/2021 (Estimated)5/6/2021 (Confirmed)4/27/2021 (Estimated)5/12/2021 (Estimated)5/6/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
 Brokerages Anticipate Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Will Announce Quarterly Sales of $97.12 Million Brokerages Anticipate Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Will Announce Quarterly Sales of $97.12 Million
americanbankingnews.com - April 13 at 3:32 AM
$0.19 EPS Expected for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) This Quarter$0.19 EPS Expected for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) This Quarter
americanbankingnews.com - April 11 at 12:08 PM
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Hold" from BrokeragesAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Hold" from Brokerages
americanbankingnews.com - April 9 at 10:48 AM
Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
finance.yahoo.com - April 9 at 9:20 AM
Have Insiders Been Selling Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares This Year?Have Insiders Been Selling Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares This Year?
nasdaq.com - April 7 at 9:20 AM
Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare ConferenceAmphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 6 at 6:32 PM
Raymond James Sticks to Their Buy Rating for ANI Pharmaceuticals (ANIP)Raymond James Sticks to Their Buy Rating for ANI Pharmaceuticals (ANIP)
smarteranalyst.com - April 5 at 7:07 PM
Amphastar Pharmaceuticals (AMPH) Receives a Buy from Northland SecuritiesAmphastar Pharmaceuticals (AMPH) Receives a Buy from Northland Securities
smarteranalyst.com - March 30 at 12:22 PM
FDA Approves New Drug Application For Amphastar’s Dextrose InjectionFDA Approves New Drug Application For Amphastar’s Dextrose Injection
finance.yahoo.com - March 30 at 12:22 PM
Amphastar Pharmaceuticals Receives FDA Approval for Dextrose InjectionAmphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection
finance.yahoo.com - March 29 at 6:19 AM
Raymond James Keeps a Hold Rating on Amphastar Pharmaceuticals (AMPH)Raymond James Keeps a Hold Rating on Amphastar Pharmaceuticals (AMPH)
smarteranalyst.com - March 16 at 10:05 AM
Amphastar: Q4 Earnings SnapshotAmphastar: Q4 Earnings Snapshot
finance.yahoo.com - March 15 at 6:56 PM
Amphastar: Q4 Earnings Snapshot | Raleigh News & ObserverAmphastar: Q4 Earnings Snapshot | Raleigh News & Observer
newsobserver.com - March 15 at 6:56 PM
Recap: Amphastar Pharmaceuticals Q4 EarningsRecap: Amphastar Pharmaceuticals Q4 Earnings
benzinga.com - March 15 at 6:56 PM
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020
finance.yahoo.com - March 15 at 6:56 PM
Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue EstimatesAmphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates
finance.yahoo.com - March 15 at 6:56 PM
Raymond James Sticks to Their Hold Rating for PLx Pharma (PLXP)Raymond James Sticks to Their Hold Rating for PLx Pharma (PLXP)
smarteranalyst.com - March 15 at 1:32 PM
Heres what Wall Street expects from Amphastar Pharmaceuticalss earnings reportHere's what Wall Street expects from Amphastar Pharmaceuticals's earnings report
markets.businessinsider.com - March 13 at 2:27 PM
Hyaluronidase Market Revenue Growth Predicted by 2021-2030 | Amphastar Pharmaceuticals Inc., PrimaPharma Inc.Hyaluronidase Market Revenue Growth Predicted by 2021-2030 | Amphastar Pharmaceuticals Inc., PrimaPharma Inc.
marketwatch.com - March 9 at 9:35 AM
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March ...Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March ...
apnews.com - March 8 at 6:28 PM
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 15th, 2021Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 15th, 2021
finance.yahoo.com - March 8 at 6:28 PM
FDA approves 1st generic glucagon injections for severe hypoglycemiaFDA approves 1st generic glucagon injections for severe hypoglycemia
ems1.com - February 25 at 8:22 PM
Teva Pharmaceutical (TEVA) Gets a Buy Rating from Raymond JamesTeva Pharmaceutical (TEVA) Gets a Buy Rating from Raymond James
smarteranalyst.com - February 16 at 2:33 PM
What Percentage Of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Do Insiders Own?What Percentage Of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Do Insiders Own?
finance.yahoo.com - February 8 at 7:26 AM
Raymond James Believes Teva Pharmaceutical (TEVA) Still Has Room to GrowRaymond James Believes Teva Pharmaceutical (TEVA) Still Has Room to Grow
smarteranalyst.com - January 19 at 10:04 PM
DateCompanyBrokerageAction
2/25/2021VBI VaccinesJefferies Financial GroupInitiated Coverage
8/27/2020VBI VaccinesOppenheimerReiterated Rating
8/26/2020VBI VaccinesRaymond JamesUpgrade
6/29/2020VBI VaccinesBMO Capital MarketsReiterated Rating
3/6/2020VBI VaccinesCanaccord GenuityReiterated Rating
1/11/2021Collegium PharmaceuticalHC WainwrightBoost Price Target
12/29/2020Collegium PharmaceuticalNeedham & Company LLCReiterated Rating
7/14/2020Collegium PharmaceuticalBWS FinancialInitiated Coverage
5/26/2020Collegium PharmaceuticalGuggenheimInitiated Coverage
2/28/2020Collegium PharmaceuticalWilliam BlairReiterated Rating
2/12/2020Collegium PharmaceuticalPiper SandlerBoost Price Target
2/7/2020Collegium PharmaceuticalCantor FitzgeraldBoost Price Target
3/22/2021Odonate TherapeuticsLifesci CapitalDowngrade
3/22/2021Odonate TherapeuticsThe Goldman Sachs GroupLower Price Target
3/22/2021Odonate TherapeuticsCowenDowngrade
9/9/2020Odonate TherapeuticsCi CapitalReiterated Rating
3/15/2019ADVANZ PHARMABloom BurtonReiterated Rating
3/23/2021Amphastar PharmaceuticalsWells Fargo & CompanyLower Price Target
10/5/2020Amphastar PharmaceuticalsNorthland SecuritiesUpgrade
3/13/2019Amphastar PharmaceuticalsPiper Jaffray CompaniesDowngrade
(Data available from 4/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.